PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reports that Thomas Moore, CEO & Chairman of Advaxis, was interviewed by Malini Chatterjee, Ph.D., Director of Research at OneMedPlace, to discuss the preliminary safety and survival data from the ongoing ADXS-HPV Phase 2 Trial in patients with recurrent/refractory cervical cancer in India that were presented at the World Cancer Immunotherapy Conference in San Diego on January 25, 2012.
